PL2275086T3 - Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania - Google Patents

Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania

Info

Publication number
PL2275086T3
PL2275086T3 PL10160099T PL10160099T PL2275086T3 PL 2275086 T3 PL2275086 T3 PL 2275086T3 PL 10160099 T PL10160099 T PL 10160099T PL 10160099 T PL10160099 T PL 10160099T PL 2275086 T3 PL2275086 T3 PL 2275086T3
Authority
PL
Poland
Prior art keywords
administration
methods
reduced volume
glatiramer acetate
volume formulation
Prior art date
Application number
PL10160099T
Other languages
English (en)
Inventor
Ayelet Altman
Doris Saltkill
Dalton L Tomlinson
Tomer El-Gad
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42283140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2275086(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PL2275086T3 publication Critical patent/PL2275086T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10160099T 2009-07-15 2010-04-15 Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania PL2275086T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27100909P 2009-07-15 2009-07-15
US27134009P 2009-07-20 2009-07-20
US33701110P 2010-01-29 2010-01-29
EP10160099A EP2275086B1 (en) 2009-07-15 2010-04-15 Reduced volume formulation of glatiramer acetate and methods of administration

Publications (1)

Publication Number Publication Date
PL2275086T3 true PL2275086T3 (pl) 2012-09-28

Family

ID=42283140

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10160099T PL2275086T3 (pl) 2009-07-15 2010-04-15 Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania

Country Status (20)

Country Link
US (3) US20110060279A1 (pl)
EP (2) EP2275086B1 (pl)
JP (1) JP2012533540A (pl)
AR (1) AR077484A1 (pl)
AT (1) ATE549013T1 (pl)
AU (1) AU2010273234A1 (pl)
BR (1) BR112012000878A2 (pl)
CA (1) CA2697570C (pl)
DK (1) DK2275086T3 (pl)
EA (1) EA201270167A1 (pl)
ES (1) ES2383347T3 (pl)
HK (1) HK1152249A1 (pl)
HR (1) HRP20120349T1 (pl)
IL (1) IL217240A0 (pl)
MX (1) MX2012000687A (pl)
PL (1) PL2275086T3 (pl)
PT (1) PT2275086E (pl)
RS (1) RS52367B (pl)
WO (1) WO2011008274A2 (pl)
ZA (1) ZA201200586B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
DK2275086T3 (da) * 2009-07-15 2012-07-09 Teva Pharma Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
EP2405749B1 (en) 2009-08-20 2013-05-08 Yeda Research and Development Co., Ltd. Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ609938A (en) 2010-10-11 2015-11-27 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
US10052436B2 (en) * 2012-08-20 2018-08-21 Carebay Europe Ltd Automatic injection device
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
WO2014128079A1 (en) * 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
KR101738889B1 (ko) * 2013-03-08 2017-05-23 테바 파마슈티컬 인더스트리즈 리미티드 주사기용 재사용 가능한 주입기 장치
JP6073507B2 (ja) * 2013-03-08 2017-02-01 テバ ファーマシューティカル インダストリーズ リミティド 注射器用の再使用可能な注入器装置
US8591463B1 (en) 2013-03-08 2013-11-26 Teva Pharmaceutical Industries Ltd. Re-useable injector device for syringe
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
RU2728195C2 (ru) 2014-02-26 2020-07-28 Аллерган, Инк. Устройство доставки внутриглазного имплантата и способы его использования
US9415176B1 (en) 2015-01-22 2016-08-16 West Pharmaceutical Services, Inc. Autoinjector having an end-of-dose visual indicator
US9155775B1 (en) * 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CA3042493A1 (en) * 2016-11-02 2018-05-11 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3600553A4 (en) 2017-03-26 2020-09-02 Mapi Pharma Ltd. GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
EP3645029B1 (en) 2017-06-26 2023-01-18 Institut Pasteur Treatments to eliminate hiv reservoirs and reduce viral load
WO2019036363A1 (en) 2017-08-14 2019-02-21 Progenity Inc. TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3673317D1 (de) * 1985-10-11 1990-09-13 Duphar Int Res Automatische spritze.
NL8701091A (nl) * 1987-05-08 1988-12-01 Spruyt Hillen Bv Injectiepen.
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8926825D0 (en) * 1989-11-28 1990-01-17 Glaxo Group Ltd Device
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6454746B1 (en) * 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
SE518981C2 (sv) 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
AU2003275895B2 (en) * 2002-11-25 2009-02-05 Tecpharma Licensing Ag Auto-injector comprising a resettable releasing safety device
CA2540890A1 (en) * 2003-10-03 2005-04-14 Bayhill Therapeutics, Inc. Treatment of demyelinating autoimmune disease with modified ordered peptides
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
WO2006029036A2 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
EP1797109B1 (en) * 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
JP5297653B2 (ja) * 2004-10-29 2013-09-25 サンド・アクチエンゲゼルシヤフト グラチラマーの製造法
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20070161960A1 (en) * 2006-01-12 2007-07-12 Fu-Yuan Li Lancet device
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
KR101396797B1 (ko) * 2006-06-30 2014-05-26 애브비 바이오테크놀로지 리미티드 자동 주사 장치
USD622374S1 (en) * 2006-09-06 2010-08-24 Abbott Biotechnology Ltd. Automatic injection device
JP2011504925A (ja) 2007-11-28 2011-02-17 テバ ファーマシューティカル インダストリーズ リミティド 臨床的に確実な多発性硬化症の発症を遅延させる方法
USD607558S1 (en) * 2008-09-19 2010-01-05 Becton Dickinson France S.A.S. Medicine injector
DK2275086T3 (da) * 2009-07-15 2012-07-09 Teva Pharma Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf

Also Published As

Publication number Publication date
US9018170B2 (en) 2015-04-28
US20110060279A1 (en) 2011-03-10
HRP20120349T1 (hr) 2012-07-31
AU2010273234A1 (en) 2012-02-23
US20110066112A1 (en) 2011-03-17
IL217240A0 (en) 2012-02-29
US7855176B1 (en) 2010-12-21
CA2697570A1 (en) 2010-06-22
ES2383347T3 (es) 2012-06-20
HK1152249A1 (en) 2012-02-24
WO2011008274A3 (en) 2011-09-22
WO2011008274A2 (en) 2011-01-20
EP2275086B1 (en) 2012-03-14
EP2275086A1 (en) 2011-01-19
ZA201200586B (en) 2013-10-30
ATE549013T1 (de) 2012-03-15
MX2012000687A (es) 2012-09-07
RS52367B (en) 2012-12-31
AR077484A1 (es) 2011-08-31
PT2275086E (pt) 2012-05-18
JP2012533540A (ja) 2012-12-27
DK2275086T3 (da) 2012-07-09
WO2011008274A4 (en) 2011-11-10
CA2697570C (en) 2011-11-01
EA201270167A1 (ru) 2012-08-30
EP2453907A2 (en) 2012-05-23
BR112012000878A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
ZA201200586B (en) Reduced volume formulation of glatiramer acetate and methods of administration
IL276157A (en) Pharmaceutical preparations and methods for transferring them related to them
HK1250313A1 (zh) 穩定的藥物組合物和使用所述組合物的方法
EP2413917A4 (en) DRUG DELIVERY SYSTEM AND METHODS OF USING THE SAME
LT2493474T (lt) Būdai ir kompozicijos prolonguotam vaistų įvedimui
GB2478849A8 (en) Improved pharmaceutical compositions and methods of delivery
IL219155A0 (en) Pharmaceutical formulations of nitrite and uses thereof
EP2558077A4 (en) ORAL PHARMACEUTICAL COMPOSITION COMPRISING FENOFIBRIC ACID AND ALKALINIZING AGENT
IL224191A (en) Compositions of vitamin d and cmc epi-14 analogues
EP2649999A4 (en) USE OF QUINAZOLIN COMPOUND IN THE PREPARATION OF ANTI-FLAVIVIRUS MEDICINE
SI2275086T1 (sl) Formulacija glatiramer acetata z zmanjšanim volumnom in postopki za dajanje
GB201012660D0 (en) Inhaler and formulation